reads mapping to overlapping genes?
Many reads are mapped to positions where overlapping genes reside. So we overestimated the number of reads mapping to some genes. How to deal with this problem?
Thank you for your time!
-
Many reads are mapped to positions where overlapping genes reside. So we overestimated the number of reads mapping to some genes. How to deal with this problem?
Thank you for your time!
-
It depends on the structure of the genes, but we've started calculating our counts as bp of read per kbp of transcript, but calculating this value separately for every exon, and then taking the mean or median value of all exons as the overall value for the gene. This seems to cut down on problems which only affect a small part of the gene.Originally posted by beliefbio View Post
Many reads are mapped to positions where overlapping genes reside. So we overestimated the number of reads mapping to some genes. How to deal with this problem?
Thank you for your time! -
Yes, this should also reduce the impact of alternative splicing. One question: if different transcripts use the same exon, do you count the corresponding value several times when computing the mean or median, or just once?Originally posted by simonandrews View PostComment
-
Take a look at our read counter tool that does not count read-pairs mapped to the same-strand overlapping part of genes: http://seqanswers.com/forums/showthread.php?p=134850
Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment